Zach focuses his practice on mergers and acquisitions, where he represents private equity sponsors and strategic acquirers in buy-side and sell-side transactions. He also advises on capital markets offerings and represents venture capital investors and high-growth companies in a variety of financing transactions.
Prior to joining Mintz, Zach was a summer associate at a Virginia-based law firm, where he assisted with M&A transactions. Before law school, he worked as a financial advisory consultant at a Big Four professional services firm.
Zach earned his JD from the Washington and Lee University School of Law. Prior to law school, he earned a BS in finance and accounting from Virginia Tech.
News & Press
Mintz advised the placement agents in connection with the $39 Million private placement that is expected to close in connection with the completion of the merger transaction between Scancell Holdings plc and Neuphoria Therapeutics Inc. The private placement is part of up to $89 million of financing expected to be raised by Scancell in connection with the merger transaction through a combination of equity and debt.
Mintz Advises on uniQure’s $259 Million Public Offering
June 25, 2026
Mintz advised the underwriters in connection with uniQure’s $259 million public offering of ordinary shares.
Mintz advised the underwriters in connection with NervGen Pharma’s $60 million public offering of common shares and accompanying warrants.
Mintz Advising on $350 Million Private Placement Concurrent with Obsidian Therapeutics’ and Galera Therapeutics’ Merger Transaction
April 17, 2026
Mintz is advising the placement agents in connection with the $350 million private placement that is expected to close immediately prior to the completion of the merger transaction between Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc.
Recent Insights
Mintz advised the placement agents in connection with the $39 Million private placement that is expected to close in connection with the completion of the merger transaction between Scancell Holdings plc and Neuphoria Therapeutics Inc. The private placement is part of up to $89 million of financing expected to be raised by Scancell in connection with the merger transaction through a combination of equity and debt.
Mintz advised the underwriters in connection with uniQure’s $259 million public offering of ordinary shares.
Mintz advised the underwriters in connection with NervGen Pharma’s $60 million public offering of common shares and accompanying warrants.
